Cerevance Media Center
Current News
May 2, 2024
Cerevance Achieves First Milestone in Research Collaboration with Merck
Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
News Archive
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Cerevance chief executive officer, Craig Thompson, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024.
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
May 16, 2023
Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Events Archive
February 15, 2023
Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome
Ossola, B., Rifat, A., Rowland, A., Hunter, H., Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A.
ViewviewNovember 21, 2022
Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction
June 30, 2021